Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Issue : The Pharmaceutical Journal, December 2014

Sort by: Newest first Oldest first A-Z Z-A

  • SMC December 2014 decisions Subscription

    18 DEC 2014 10:31

    In the latest round of decisions by the Scottish Medicines Consortium(SMC), a number of medicines have been accepted for use in NHS Scotland; obinutuzumab (Gazyvaro; Roche), pemetrexed (Alimta; Eli Lilly), pomalidomide (Imnovid; Celegene), umeclidinium (Incruse; GlaxoSmithKline), cholecalciferol 25,000 international units oral solution ...

  • Rezolsta available for HIV Subscription

    17 DEC 2014 17:02

    Rezolsta, a darunavir 800mg and cobicistat 150mg combination tablet, is now available from Janssen for the treatment of HIV in adults. NHS list price, 30 tablets, £317.24. 

  • E-cigarettes and tobacco control in Scotland Subscription

    17 DEC 2014 17:00

    The Scottish Government is consulting on proposals to limit young people’s access to e-cigarettes and to curb smoking in cars with young people. Full details of the proposals can be found on the Scottish government’s website. Comments can be submitted until 2 January 2015. 

  • Managing diabetes NPA resource Subscription

    17 DEC 2014 17:00

    The National Pharmacy Association (NPA) has produced a diabetes resource pack for community pharmacy. ‘Managing diabetes in community pharmacy’ will be distributed to members of the NPA in December 2014. 

  • Risk of hyperglycaemia for diabetes patients using faulty insulin pens Subscription

    17 DEC 2014 16:45

    People with diabetes using insulin pens from a number of faulty batches manufactured by Owen Mumford are at risk of hyperglycaemia.

  • Sick day rules for reducing patients’ risk of acute kidney injury (AKI)

    Initiative seeks to protect patients from acute kidney injury

    16 DEC 2014 15:08 By Gareth Malson

    If you have not yet heard of sick day rules for reducing patients’ risk of acute kidney injury (AKI), you probably will soon.

  • Sue Sharpe, the chief executive of the Pharmaceutical Services Negotiating Committee, said that when NHS England launched its consultation, it said the sector could expect a further document on the proposed features of its strategic framework for commissi

    Leaders undeterred by missing commissioning plan for pharmacy Subscription

    15 DEC 2014 16:39 By Ingrid Torjesen
    Comments (1)

    Pharmacy bodies remain hopeful that pharmacy will play a meaningful role in new models of NHS care, despite the lack of a formal response to the Call to Action consultation.

  • Use of antiretroviral therapy could contribute to a reduction in HIV virulence at the population level, study finds

    Use of antiretroviral therapy will drive down HIV virulence Subscription

    15 DEC 2014 16:35
    Comments (1)

    HIV is evolving relatively rapidly, which is contributing to a reduction in HIV virulence at the population level, say researchers writing in PNAS.

  • Clinical trials of the VSV-ZEBOV Ebola vaccine have been halted because some participants developed joint pain after receiving the injection, says a press release issued by the University Hospitals of Geneva

    Ebola clinical trial suspended after volunteers complain of joint pains Subscription

    12 DEC 2014 16:49 By Joanna Lyford

    A phase I clinical trial of the fast-tracked Ebola vaccine VSV-ZEBOV has been halted in Switzerland because some trial participants developed mild joint pain.

  • Duaklir Genuair now available Subscription

    12 DEC 2014 11:30

    Duaklir Genuair (aclidinium bromide and formoterol fumarate) dry powder inhaler 340μg/12μg is now available from AstraZeneca for use as a maintenance brochodilator to relieve symptoms of chronic obstructive pulmonary disease in adults. Net price: 1 x 60-dose inhaler, £32.50.

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.